KLK3 and prostate carcinoma: For prostate cancer, patients receiving PDT had a biopsy-negative rate of 55%, a prostate specific antigen decrease rate of 36%, and a failure-free survival rate of 77%, and the positive biopsy rate for vascular-targeted PDT was 36%.